Completed PHASE3 INTERVENTIONAL 2-arm NCT02251977

Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer

The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial

Sponsor: Yuhong Li

Conditions Chemotherapy-induced Neutropenia Colorectal Cancer

Interventions GM1 mFOLFOX6 or XELOX placebo

Updated 6 times since 2017 Last updated: Oct 3, 2019 Started: Sep 30, 2014 Primary completion: Sep 5, 2017 Completion: Sep 5, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chemotherapy-induced Neutropenia and Colorectal Cancer and is currently completed. Yuhong Li leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yuhong Li

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China